Inactive Instrument
Claritas Pharmaceuticals Stock Toronto S.E.
Stocks
KLY
CA1806341071
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 5.37M 3.81M 3.35M 3.11M 2.86M 367M 5.45M 36.97M 14.45M 180M 14.31M 14M 624M | P/E 2019 |
-0.74x | P/E 2020 | 0.13x |
|---|---|---|---|---|---|
| Enterprise Value | 6.29M 4.47M 3.92M 3.65M 3.35M 430M 6.39M 43.31M 16.92M 211M 16.76M 16.4M 731M | EV / Sales 2019 |
-
| EV / Sales 2020 | - |
| Free-Float |
99.74% | Yield 2019 * |
-
| Yield 2020 | - |
| 1 day | +11.11% |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CEO | Chief Executive Officer | 76 | 21/06/2017 |
Victoria Rudman
DFI | Director of Finance/CFO | 58 | 29/06/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Farrell
CHM | Chairman | 76 | 18/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +11.11% | -.--% | - | - | 37 | |
| +1.07% | -3.49% | -3.35% | +10.44% | 46.86B | |
| +0.25% | +1.65% | +399.22% | +634.87% | 40.23B | |
| -0.27% | +4.45% | +11.81% | +65.64% | 36.23B | |
| +0.35% | +0.87% | +4.46% | -10.16% | 34.72B | |
| +3.14% | +1.02% | +4.76% | +40.92% | 27.89B | |
| -0.73% | +11.84% | +34.39% | +134.36% | 16.79B | |
| +0.47% | -2.74% | - | - | 16.74B | |
| +0.42% | -5.52% | -3.43% | +9.03% | 13.12B | |
| -2.68% | -2.49% | -11.36% | -33.61% | 12.7B | |
| Average | +1.31% | +0.83% | +54.56% | +106.44% | 27.25B | |
| Weighted average by Cap. | +0.48% | +0.91% | +74.42% | +136.27% |
| 2019 | 2020 | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.21M -15.06M -13.23M -12.3M -11.29M -1.45B -21.54M -146M -57.08M -713M -56.54M -55.33M -2.47B | 4.21M 2.99M 2.63M 2.44M 2.24M 288M 4.27M 29M 11.33M 142M 11.22M 10.98M 489M |
| Net Debt | 704K 500K 439K 408K 375K 48.14M 715K 4.85M 1.89M 23.67M 1.88M 1.84M 81.83M | 920K 653K 574K 534K 490K 62.91M 934K 6.34M 2.48M 30.93M 2.45M 2.4M 107M |
Employees
-
